- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07656792
A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of BI 3031185 in Japanese Healthy Male Trial Participants (Single-blind, Randomised, Placebo-controlled, Parallel Group Design) and Effect of Multiple Doses of BI 3031185 on Pharmacokinetics of a Single Dose of a Combination of Drospirenone and Ethinylestradiol (Oral Contraceptive) in Japanese Healthy Female Trial Participants (Non-randomised, Open-label, Fixed Sequence Design)
Single dose (SD) part: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male trial participants following oral administration of single dose.
Multiple doses (MD) part: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male trial participants following oral administration of multiple doses.
Oral contraceptives (OC) part: The main objective of this trial is to investigate the effect of multiple oral doses of BI 3031185 on pharmacokinetics of drospirenone (DRSP) and ethinylestradiol (EE) (YAZ®) in Japanese healthy female trial participants.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Boehringer Ingelheim
- Número de telefone: 1-800-243-0127
- E-mail: clintriage.rdg@boehringer-ingelheim.com
Locais de estudo
-
-
-
Fukuoka, Fukuoka, Japão, 813-0017
- Fukuoka Mirai Hospital
-
Contato:
- Boehringer Ingelheim
- Número de telefone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion criteria:
Single dose (SD) and multiple doses (MD) part: Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12- lead electrocardiogram (ECG), and clinical laboratory tests Oral contraceptives (OC) part: Women of non-childbearing potential (WONCBP) who meet postmenopausal or surgically sterilised according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
- Postmenopausal, defined as no menses for 1 year without an alternative medical cause.
- Surgically sterilised (including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy)
- SD and MD part: Age of 18 to 45 years (inclusive) OC part: Age of 18 to 64 years (inclusive)
- Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
- Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
Exclusion criteria:
- Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- Repeated measurement of systolic blood pressure outside the range of 90 to 139 mmHg, diastolic blood pressure outside the range of 40 to 89 mmHg, or pulse rate outside the range of 45 to 99 bpm
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: SD part: BI 3031185
SD = Single dose
|
BI3031185
|
|
Experimental: SD Part: Placebo matching BI 3031185
|
Placebo matching BI 3031185
|
|
Experimental: MD part: Midazolam and BI 3031185
MD = Multiple doses
|
Midazolam
Outros nomes:
BI3031185
|
|
Experimental: MD Part: Midazolam and Placebo matching BI 3031185
|
Midazolam
Outros nomes:
Placebo matching BI 3031185
|
|
Experimental: OC part: YAZ® and BI 3031185
OC = Oral contraceptives
|
BI3031185
YAZ®
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
SD part: Occurrence of any treatment-emergent adverse event (AE) assessed as drug-related by the investigator
Prazo: Up to 29 days
|
SD = Single dose
|
Up to 29 days
|
|
MD part: Occurrence of any treatment-emergent adverse event (AE) assessed as drug-related by the investigator
Prazo: Up to 47 days
|
MD = Multiple doses
|
Up to 47 days
|
|
OC part: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Prazo: Up to 29 days
|
OC = Oral contraceptives
|
Up to 29 days
|
|
OC part: Maximum measured concentration of the analyte in plasma (Cmax)
Prazo: Up to 29 days
|
Up to 29 days
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
SD part: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Prazo: Up to 11 days
|
Up to 11 days
|
|
SD part: Maximum measured concentration of the analyte in plasma (Cmax)
Prazo: Up to 11 days
|
Up to 11 days
|
|
MD part: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Prazo: Up to 39 days
|
Up to 39 days
|
|
MD part: Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Prazo: Up to 39 days
|
Up to 39 days
|
|
OC part: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Prazo: Up to 29 days
|
Up to 29 days
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1516-0005
- U1111-1331-6622 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to:
https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Midazolam
-
Diskapi Yildirim Beyazit Education and Research...Ainda não está recrutandoAnestesia Pediátrica | Pré-medicaçãoTurquia (Türkiye)
-
SYED HAIDER ALIAinda não está recrutandoGestão da Sedação e Analgesia em Doentes Submetidos a Broncoscopia Flexível
-
PfizerConcluído
-
University of Tennessee Graduate School of MedicineConcluídoSedação | VasectomiaEstados Unidos
-
Sohag UniversityAinda não está recrutandoCirurgia VitreorretinianaEgito
-
Postgraduate Institute of Dental Sciences RohtakInscrevendo-se por convite
-
Seattle Children's HospitalConcluído
-
Zhuji People's Hospital of Zhejiang ProvinceConcluídoCesáriana | Eficácia | Segurança | Pré-eclâmpsia | MidazolamChina
-
Jiangsu HengRui Medicine Co., Ltd.ConcluídoGota e HiperuricemiaChina
-
Kasr El Aini HospitalRecrutamentoDelírio de emergênciaEgito